This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK
Drug Safety Open Access 23 December 2019
-
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
Drug Safety Open Access 30 December 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Louët, S. Lessons from Eprex for biogeneric firms. Nat Biotechnol 21, 956–957 (2003). https://doi.org/10.1038/nbt0903-956
Issue Date:
DOI: https://doi.org/10.1038/nbt0903-956
This article is cited by
-
The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK
Drug Safety (2020)
-
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
Drug Safety (2016)
-
Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease
Drugs (2013)
-
Biosimilar Growth Hormone
The Indian Journal of Pediatrics (2012)
-
Current Status of Biosimilar Growth Hormone
International Journal of Pediatric Endocrinology (2009)